Sulfamethoxazole enhances the antimycobacterial activity of rifampicin

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2908-2911

  Macingwana, Lubabalo ^a   Baker, Bienyameen ^a   Ngwane, Andile H ^a   Harper, Catriona ^a   Cotton, Mark F ^a   Hesseling, Anneke ^a   Diacon, Andreas H ^a   van Helden, Paul ^a   Wiid, Ian ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Ethambutol; Isoniazid; Synergy; Trimethoprim

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTITUBERCULAR AGENTS; DRUG SYNERGISM; ETHAMBUTOL; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

EID: 84869484254     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks306     Document Type: Article

References (14)

1. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11: 551-81.
2. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17: 770-82.
3. Libecco JA, Powell KR. Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev 2004; 25: 375-80.
4. Forgacs P, Wengenack NL, Hall L et al. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2009; 53: 4789-93.
5. Tortoli E, Piersimoni C, Bacosi D et al. Isolation of the newly described species Mycobacterium celatum from AIDS patients. J Clin Microbiol 1995; 33: 137-40.
6. Siddiqi SH. Bactec TB System, Product and Procedure Manual, Revision B. Towson, MD, USA: Becton Dickinson Diagnostic Instrument Systems, 1989.
7. Hoffner SE, Svenson SB, Källenius G. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol 1987; 6: 530-5.
8. Winslow DL, Pankey GA. In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes. Antimicrob Agents Chemother 1982; 22: 51-4.
9. Wen X, Wang J-S, Backman JT et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002; 30: 631-5.
10. Varoquaux O, Lajoie D, Gobert C et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Br J Clin Pharmacol 1985; 20: 575-81.
11. Wiktor SZ, Sassan-Morokro M, Grant AD et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-75.
12. Ong W, Stevens A, Leslie DE. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob Agents Chemother 2010; 54: 2748-9.
13. Tripathi RP, Tewari N, Dwivedi N et al. Fighting tuberculosis: an old disease with new challenges. Med Res Rev 2005; 25: 93-131.
14. Hartmann G, Honikel KO, Knüsel F et al. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 1967; 145: 843-4.